Hyloris to Report 2023 Full-Year Results on 14 March 2024
March 08 2024 - 1:00AM
UK Regulatory
Hyloris to Report 2023 Full-Year Results on 14 March 2024
Liège, Belgium – 08 February 2024, 07:00
AM CET – Non-regulated information – Hyloris Pharmaceuticals SA
(Euronext Brussels: HYL), a specialty biopharma company
committed to addressing unmet medical needs through reinventing
existing medications, today announces that it will release its full
year 2023 fiscal results on Thursday, 14 March 2024, at 07.00 AM
CET.
Following the release, the company will host a
live webcast to discuss 2023 results and the outlook for 2024.
Participants will have a chance to interact with Stijn Van Rompay,
CEO and Jean-Luc Vandebroek, CFO in a question-and-answer session.
The details of the event are below:
Date: Thursday, 14 March
Time: 02.00pm CET
Registration: Hyloris Annual Results 2023
Webcast
About Hyloris Pharmaceuticals
SA
Hyloris is a specialty biopharma company focused
on innovating, reinventing, and optimizing existing medications to
address important healthcare needs and deliver relevant
improvements for patients, healthcare professionals and payors.
The Company’s development strategy primarily focuses on leveraging
established regulatory pathways, such as the FDA’s 505(b)2 pathway
in the U.S or equivalent regulatory frameworks in other regions
which are specifically designed for pharmaceuticals for which
safety and efficacy of the molecule have already been established.
This approach can reduce the clinical burden required for market
entry, and significantly shorten the development timelines, leading
to reduced costs and risks.
Hyloris has built a broad, patented portfolio of
18 reformulated and repurposed value-added medicines that have the
potential to offer significant advantages over existing
alternatives. Two products are currently in early phases of
commercialization in collaboration with commercial partners:
Sotalol IV for the treatment of atrial fibrillation, and Maxigesic®
IV, a non-opioid post-operative pain treatment. In addition to its
core strategic focus, the Company has 1 approved high barrier
generic product launched in the U.S. and 2 high barrier generic
products in development.
Hyloris is based in Liège, Belgium. For more
information, visit www.hyloris.com and follow-us
on LinkedIn.
For more information, contact
Hyloris:
Stijn Van Rompay, CEO
Stijn.Vanrompay@hyloris.com
+32 (0)4 346 02 07
Jean-Luc Vandebroek, CFO
Jean-luc.vandebroek@hyloris.com
+32 (0)478 27 68 42
Jessica McHargue, Investor Relations & Communications
Jessica.mchargue@hyloris.com
+1 (919) 451 4740
Disclaimer and forward-looking
statements
Hyloris means “high yield, lower risk”, which
relates to the 505(b)(2) regulatory pathway for product approval on
which the Issuer focuses, but in no way relates or applies to an
investment in the Shares.
Certain statements in this press release are “forward-looking
statements.” These forward-looking statements can be identified
using forward-looking terminology, including the words "believes",
"estimates," "anticipates", "expects", "intends", "may", "will",
"plans", "continue", "ongoing", "potential", "predict", "project",
"target", "seek" or "should", and include statements the Company
makes concerning the intended results of its strategy. These
statements relate to future events or the Company’s future
financial performance and involve known and unknown risks,
uncertainties, and other factors, many of which are beyond the
Company’s control, that may cause the actual results, levels of
activity, performance or achievements of the Company or its
industry to be materially different from those expressed or implied
by any forward-looking statements. The Company undertakes no
obligation to publicly update or revise forward-looking statements,
except as may be required by law.
- 20240307 Full Year Results Release Date_ENG
Hyloris Pharmaceuticals (LSE:0AB6)
Historical Stock Chart
From Jul 2024 to Aug 2024
Hyloris Pharmaceuticals (LSE:0AB6)
Historical Stock Chart
From Aug 2023 to Aug 2024